Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients

The Angioedema Activity Score (AAS) is recommended by the EAACI/GA2LEN/EDF/WAO guidelines for urticaria as the standard measure for assessing disease activity in patients with recurrent angioedema (RAE). To date, it has been translated into 80 languages for use in 52 countries, but it has not been f...

Full description

Bibliographic Details
Main Authors: Kanokvalai Kulthanan, Leena Chularojanamontri, Chuda Rujitharanawong, Puncharas Weerasubpong, Karsten Weller, Marcus Maurer
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2019/9157895
id doaj-b0572caf04e9403ab47870cc6c9ae689
record_format Article
spelling doaj-b0572caf04e9403ab47870cc6c9ae6892020-11-25T00:12:40ZengHindawi LimitedBioMed Research International2314-61332314-61412019-01-01201910.1155/2019/91578959157895Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian PatientsKanokvalai Kulthanan0Leena Chularojanamontri1Chuda Rujitharanawong2Puncharas Weerasubpong3Karsten Weller4Marcus Maurer5Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDepartment of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDepartment of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDepartment of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité–Universitätsmedizin Berlin, Berlin, GermanyDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité–Universitätsmedizin Berlin, Berlin, GermanyThe Angioedema Activity Score (AAS) is recommended by the EAACI/GA2LEN/EDF/WAO guidelines for urticaria as the standard measure for assessing disease activity in patients with recurrent angioedema (RAE). To date, it has been translated into 80 languages for use in 52 countries, but it has not been formally validated in Asian patient populations. As RAE may be different in Asian and non-Asian patients, it is important to validate and characterize the reliability of tools to assess RAE disease activity in Asian patients. This study proposed to demonstrate the validity and reliability of the AAS in Asian patients. Accordingly, this study aimed to generate and validate the Thai version of the AAS and to characterize its reliability in Asian patients, specifically in Thailand. A structured translation was conducted with approval from the original authors. The Patient Global Assessment of Disease Activity (PGA-DA) was used as an instrument to compare with the Thai version of the AAS. In total, 86 patients with RAE participated in the study. Seventy-six (88%) patients had RAE with chronic spontaneous urticaria. The Thai AAS was found to be a valid and reliable instrument, with high convergent and known-groups validities, excellent internal consistency, and good test-retest reliability. The validity and reliability of the AAS for assessing RAE disease activity in Asian patients have been demonstrated by our study, making it the first to do so. This will help promote the use of the AAS, in clinical trials and practice, in Asia. It will also facilitate the comparison of disease activity in patients with RAE inside and outside Asia in future studies. However, a limitation of this study was its small number of patients.http://dx.doi.org/10.1155/2019/9157895
collection DOAJ
language English
format Article
sources DOAJ
author Kanokvalai Kulthanan
Leena Chularojanamontri
Chuda Rujitharanawong
Puncharas Weerasubpong
Karsten Weller
Marcus Maurer
spellingShingle Kanokvalai Kulthanan
Leena Chularojanamontri
Chuda Rujitharanawong
Puncharas Weerasubpong
Karsten Weller
Marcus Maurer
Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients
BioMed Research International
author_facet Kanokvalai Kulthanan
Leena Chularojanamontri
Chuda Rujitharanawong
Puncharas Weerasubpong
Karsten Weller
Marcus Maurer
author_sort Kanokvalai Kulthanan
title Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients
title_short Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients
title_full Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients
title_fullStr Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients
title_full_unstemmed Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients
title_sort angioedema activity score (aas): a valid and reliable tool to use in asian patients
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2019-01-01
description The Angioedema Activity Score (AAS) is recommended by the EAACI/GA2LEN/EDF/WAO guidelines for urticaria as the standard measure for assessing disease activity in patients with recurrent angioedema (RAE). To date, it has been translated into 80 languages for use in 52 countries, but it has not been formally validated in Asian patient populations. As RAE may be different in Asian and non-Asian patients, it is important to validate and characterize the reliability of tools to assess RAE disease activity in Asian patients. This study proposed to demonstrate the validity and reliability of the AAS in Asian patients. Accordingly, this study aimed to generate and validate the Thai version of the AAS and to characterize its reliability in Asian patients, specifically in Thailand. A structured translation was conducted with approval from the original authors. The Patient Global Assessment of Disease Activity (PGA-DA) was used as an instrument to compare with the Thai version of the AAS. In total, 86 patients with RAE participated in the study. Seventy-six (88%) patients had RAE with chronic spontaneous urticaria. The Thai AAS was found to be a valid and reliable instrument, with high convergent and known-groups validities, excellent internal consistency, and good test-retest reliability. The validity and reliability of the AAS for assessing RAE disease activity in Asian patients have been demonstrated by our study, making it the first to do so. This will help promote the use of the AAS, in clinical trials and practice, in Asia. It will also facilitate the comparison of disease activity in patients with RAE inside and outside Asia in future studies. However, a limitation of this study was its small number of patients.
url http://dx.doi.org/10.1155/2019/9157895
work_keys_str_mv AT kanokvalaikulthanan angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients
AT leenachularojanamontri angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients
AT chudarujitharanawong angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients
AT puncharasweerasubpong angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients
AT karstenweller angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients
AT marcusmaurer angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients
_version_ 1725398200816238592